Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (12144)	9/7/2005 10:36:28 AM
From: StoxRider	Respond to of 37387

<< what I don't get is why so many folks out there are so keen to sell their winners too soon but let their losses run... I try to do the opposite >> well put, I have a core position with HOM and have been trading around that

To: Crossy who wrote (12144)	9/7/2005 1:24:22 PM
From: Patentlawmeister	Read Replies (2) \| Respond to of 37387

I think the tendency to sell winners too soon is based in part on fear - the fear of losing those profits of course. Psychologically it's probably easier to sell a winner than taking a loss. Well, i'm certainly not a financial advisor but what i can advise people is to have a plan from the getgo whenever you enter a position. I.e., why are you buying (you think it's worth more) and when it gets to where you think it's worth, do you sell? That's what i try to do, anyway. Today i bought CTE right after the release in the low 2's, i think this one has potential to go higher, only $45M mkt. cap and a good balance sheet: CardioTech Receives FDA Clearance for Heparin-Coated Auto Transfusion and Cardiotomy Products Wednesday September 7, 10:07 am ET WILMINGTON, Mass., Sept. 7 /PRNewswire-FirstCall/ -- CardioTech International, Inc. (Amex: CTE - News) today announced that its wholly owned subsidiary, Gish Biomedical Inc. ("Gish") has received FDA clearance for its auto transfusion and cardiotomy reservoir products with GBS® Coating for the cardiopulmonary surgery market. The potential market for coated heart-lung bypass products in the U.S. is estimated at $250 million annually. The worldwide market for heart-lung products is estimated at $500 million annually. ADVERTISEMENT The GBS® (Gish Biocompatible Surface) Coating is a proprietary covalently bonded heparin based coating developed at Gish. GBS® is a biocompatible coating and is composed of heparin and hyaluronic acid, or hyaluronan. Hyaluronan is a hydrophilic biopolymer that occurs naturally in the human body. Because it is found in extracellular matrices, is blood compatible and lacks immunogenicity, hyaluronan is a perfect coating for blood-contacting applications. Stephen DiRocco, General Manager of Gish, stated, "We are pleased to have now received FDA clearance for the full line of cardiopulmonary products used in open heart surgery with our GBS® Coating. Gish sells heart-lung bypass products to over 300 hospitals worldwide. We believe the full line of GBS® Coated products now provides us with more opportunity to increase our market share of heparin based products. Our final objective of the GBS® Coating project is to gain CE marking to sell GBS® Coated products in the European Union. A larger percent of customers in the European Union demand coated products versus the U.S. market. We have started this process and expect completion in the first quarter of 2006." About CardioTech CardioTech International, Inc. maintains operations in Wilmington, Massachusetts, Plymouth, Minnesota and Rancho Santa Margarita, California. CardioTech focuses on developing, manufacturing and marketing devices to surgically treat cardiovascular disease. Current revenue sources include patented polyurethanes, medical devices, contract manufacturing, and disposables used during cardiopulmonary bypass procedures. CardioTech is currently conducting human clinical trials with a synthetic coronary artery bypass graft that addresses a $1 billion annual market. Additionally, CardioTech has partnered with Implant Sciences and CorNova to develop a drug- eluting stent that addresses a $1 billion international market.

To: Crossy who wrote (12144)	9/7/2005 4:06:13 PM
From: badog	Read Replies (1) \| Respond to of 37387

Crossy, Regarding 'selling the winners too soon and letting the losers run': Many would then assume that ALY currently should be sold as they jumped in between $11-$12 and ALY now seems to be stuck in the $10 range since shortly after the secondary. Quite honestly, I doubt that this is what you meant because I also assume that you normally base your buys and sells more on future outlook and potential and not on short term price fluctuations. And with a stock like ALY, it has not had much time yet to run out its current plan...at least not much time since you first mentioned it. Once one gets into an investment it seems logical to at least give it time to perform. Then if management consistantly falls short of prior guidance it may be time to exit...i.e. TMY had dissapointed many investors enough times to cause even some long term holders to reconsider their investment yet had they held on it would be looking better currently. The problem that most of us encounter is just how long we anticipate sitting on dead money...or underwater. Again, ALY has not mentioned any bad news. A little dilution, but not significant. It certainly seems to me that ALY has more potential to go up then it does to go down further.... increased business after Katrina, extra income from the new equipment, and I read that Halliburton was raising it rates in oil services next month. I'm not sure that there is a correlation between Halliburton's oil services and ALY's oil services but I intend to check. Anyway it would seem that ALY has more reasons to go up then it does to go down so I hope that most will not sell just because they are temporarially under water and now consider ALY a loser. Badog